Chronoscale Corp（CHRN）の株式分析CHRNChronoscale Corp

ChronoScale Corporation, formerly Ekso Bionics Holdings, Inc., designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The Company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. It assists people to perform challenging repetitive tasks for extended periods. It operates in the Healthcare sector.

Currently, CHRN is not a strong buy due to its low RSI of 32.93, indicating it is oversold, and a significant drop of 25.59% over the past 20 days. However, it has a positive YTD change of 25.17%, suggesting some resilience. The forward P/E ratio is 0, indicating uncertainty in future earnings, and the gross margin has turned negative at -9.99% in Q3 2026, which raises concerns about profitability. The main risk is the high debt level, with total debt at $56.6 million, which could impact financial stability moving forward.